Results 171 to 180 of about 853,609 (266)
Clinical features, management, and outcomes of pulmonary mucormycosis: a decade-long retrospective study from a single center in central China. [PDF]
Yang C +7 more
europepmc +1 more source
A hyaluronic acid/tannic acid‐engineered Prussian blue oxygen nanogenerator loaded with IR780 is developed to enhance melanoma phototherapy. By integrating tumor targeting, oxygen self‐supply, and dual‐mode glutathione depletion, the nanoplatform effectively overcomes hypoxia and antioxidant defenses, potentiating synergistic photothermal/photodynamic ...
Chai‐How Hsu +7 more
wiley +1 more source
Mixed methods analysis of the cultural acceptability and competence of SNAP in Rhode Island and Connecticut. [PDF]
Elenio E +5 more
europepmc +1 more source
Rare‐Earth–Functionalized Carbon Dot Hydrogels as Mechanically Robust Antibacterial Wound Dressings
The schematic depicts a dynamically cross‐linked PVA hydrogel network in which reversible borate ester bonds and hydrogen‐bonding interactions integrate lanthanum‐doped carbon dots (La‐CDs) and dipotassium glycyrrhizinate (DPG) to form a mechanically robust, multifunctional matrix.
Shih‐Han Tsai +4 more
wiley +1 more source
Clinician perspectives on blood culture practice and diagnostic stewardship in regional emergency departments. [PDF]
Thomas E +3 more
europepmc +1 more source
A spatially controlled embedded bioprinting strategy enables precise engineering of prevascularized multicellular spheroids within skin‐derived dECM bioinks. Optimized spheroid size, composition, and spacing promote vascular maturation, paracrine signaling, and tissue integration, resulting in enhanced angiogenesis, blood perfusion, and functional skin
Minjun Ahn +6 more
wiley +1 more source
Translation-driven design: development of an antibiotic-loaded hydrogel for the management of orthopaedic device-related infection. [PDF]
Siverino C +11 more
europepmc +1 more source
Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development
LATs release drug from a tissue‐resident depot over weeks to months, improving adherence, but their development is hampered by preclinical models that cannot reproduce the coupled tissue processes, sustained release, local microenvironment change, interstitial transport, immune and foreign‐body responses, and clearance that govern depot performance in ...
Charlie Gowans +7 more
wiley +1 more source

